Lenglet Gaëlle, David-Cordonnier Marie-Hélène
INSERM U-837, Jean-Pierre Aubert Research Center (JPARC), Team 4 Molecular and Cellular Targeting for Cancer Treatment, Institute for Research on Cancer of Lille (IRCL), Lille F-59045, France.
J Nucleic Acids. 2010 Jul 25;2010:290935. doi: 10.4061/2010/290935.
DNA targeting drugs represent a large proportion of the actual anticancer drug pharmacopeia, both in terms of drug brands and prescription volumes. Small DNA-interacting molecules share the ability of certain proteins to change the DNA helix's overall organization and geometrical orientation via tilt, roll, twist, slip, and flip effects. In this ocean of DNA-interacting compounds, most stabilize both DNA strands and very few display helix-destabilizing properties. These types of DNA-destabilizing effect are observed with certain mono- or bis-intercalators and DNA alkylating agents (some of which have been or are being developed as cancer drugs). The formation of locally destabilized DNA portions could interfere with protein/DNA recognition and potentially affect several crucial cellular processes, such as DNA repair, replication, and transcription. The present paper describes the molecular basis of DNA destabilization, the cellular impact on protein recognition, and DNA repair processes and the latter's relationships with antitumour efficacy.
无论是从药品品牌还是处方量来看,DNA靶向药物在实际的抗癌药物药典中都占很大比例。与DNA相互作用的小分子具有某些蛋白质通过倾斜、滚动、扭曲、滑动和翻转效应来改变DNA螺旋整体结构和几何取向的能力。在这片与DNA相互作用的化合物海洋中,大多数能使DNA的两条链都稳定下来,只有极少数具有螺旋去稳定化特性。某些单嵌入剂或双嵌入剂以及DNA烷基化剂(其中一些已被开发或正在被开发为抗癌药物)会产生这类DNA去稳定化效应。局部不稳定的DNA部分的形成可能会干扰蛋白质/DNA识别,并可能影响几个关键的细胞过程,如DNA修复、复制和转录。本文描述了DNA去稳定化的分子基础、对蛋白质识别的细胞影响、DNA修复过程以及后者与抗肿瘤疗效的关系。